Opthea Limited (AU:OPT) has released an update.
Opthea Limited, a clinical-stage biopharmaceutical company, has been included in the S&P/ASX 300 Index as of September 23, 2024, a move reflecting its recent financial strengthening and advancement in its Phase 3 clinical trials. The company is focused on developing treatments for retinal diseases, such as wet age-related macular degeneration, and anticipates important data readouts in 2025 that could lead to FDA approval. This inclusion in the index could attract a more diversified institutional shareholder base and bolster the company’s visibility in the financial markets.
For further insights into AU:OPT stock, check out TipRanks’ Stock Analysis page.
